iHope

iHope Bio (Beijing iHope Bioscience) is a clinical-stage biotechnology company specializing in the development of innovative cell therapies, particularly Chimeric Antigen Receptor T-cell (CAR-T) and TCR-T therapies. The company focuses on addressing unmet medical needs in both hematological malignancies and refractory solid tumors. Its lead program, IH-001, is a CD19-targeted CAR-T therapy currently in Phase 2 clinical trials for B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma. iHope Bio's pipeline also includes next-generation bispecific CAR-T candidates and therapies targeting solid tumor antigens such as GPC3 and Mesothelin. Headquartered in Beijing, the company leverages its proprietary manufacturing and optimization platforms to provide high-efficacy, accessible immunotherapy solutions.